Roche Holding AG EBIT 2010-2024 | RHHBY
Roche Holding AG annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
- Roche Holding AG EBIT for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Roche Holding AG EBIT for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Roche Holding AG 2024 annual EBIT was $15.24B, a 11.13% decline from 2023.
- Roche Holding AG 2023 annual EBIT was $17.148B, a 6.36% decline from 2022.
- Roche Holding AG 2022 annual EBIT was $18.313B, a 7.8% decline from 2021.
Roche Holding AG Annual EBIT
(Millions of US $) |
| 2024 |
$15,240 |
| 2023 |
$17,148 |
| 2022 |
$18,313 |
| 2021 |
$19,863 |
| 2020 |
$19,778 |
| 2019 |
$17,662 |
| 2018 |
$15,100 |
| 2017 |
$13,215 |
| 2016 |
$14,284 |
| 2015 |
$14,384 |
| 2014 |
$15,419 |
| 2013 |
$17,678 |
| 2012 |
$15,073 |
| 2011 |
$15,234 |
| 2010 |
$11,332 |
| 2009 |
$11,926 |
Roche Holding AG Quarterly EBIT
(Millions of US $) |
| 2024-12-31 |
|
| 2024-06-30 |
|
| 2023-12-31 |
|
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$248.931B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
